MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 577757 | Name: Mitiperstat
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mitiperstat is a myeloperoxidase inhibitor.

Chemical Structure

Mitiperstat
Mitiperstat
CAS#1933460-19-5

Theoretical Analysis

MedKoo Cat#: 577757

Name: Mitiperstat

CAS#: 1933460-19-5

Chemical Formula: C15H15ClN4OS

Exact Mass: 334.0655

Molecular Weight: 334.82

Elemental Analysis: C, 53.81; H, 4.52; Cl, 10.59; N, 16.73; O, 4.78; S, 9.58

Price and Availability

Size Price Availability Quantity
10mg USD 550.00 2 Weeks
25mg USD 950.00 2 Weeks
50mg USD 1,650.00 2 Weeks
100mg USD 2,950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Mitiperstat; AZD4831; AZD-4831; AZD 4831;
IUPAC/Chemical Name
1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
InChi Key
BHKKSKOHRFHHIN-MRVPVSSYSA-N
InChi Code
InChI=1S/C15H15ClN4OS/c1-8(17)11-6-10(16)3-2-9(11)7-20-12-4-5-18-13(12)14(21)19-15(20)22/h2-6,8,18H,7,17H2,1H3,(H,19,21,22)/t8-/m1/s1
SMILES Code
O=C(N1)C(NC=C2)=C2N(CC3=CC=C(Cl)C=C3[C@H](N)C)C1=S
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 334.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Inghardt T, Antonsson T, Ericsson C, Hovdal D, Johannesson P, Johansson C, Jurva U, Kajanus J, Kull B, Michaëlsson E, Pettersen A, Sjögren T, Sörensen H, Westerlund K, Lindstedt EL. Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction. J Med Chem. 2022 Sep 8;65(17):11485-11496. doi: 10.1021/acs.jmedchem.1c02141. Epub 2022 Aug 25. Erratum in: J Med Chem. 2022 Oct 3;: PMID: 36005476; PMCID: PMC9469207. 2: Nelander K, Lagerstrom-Fermer M, Amilon C, Michaëlsson E, Heijer M, Kjaer M, Russell M, Han D, Lindstedt EL, Whatling C, Gan LM, Ericsson H. Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction. Clin Transl Sci. 2021 May;14(3):812-819. doi: 10.1111/cts.12859. Epub 2021 May 2. PMID: 32770730; PMCID: PMC8212712. 3: Inghardt T, Antonsson T, Ericsson C, Hovdal D, Johannesson P, Johansson C, Jurva U, Kajanus J, Kull B, Michaëlsson E, Pettersen A, Sjögren T, Sörensen H, Westerlund K, Lindstedt EL. Correction to "Discovery of AZD4831, a Mechanism- Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction". J Med Chem. 2022 Oct 13;65(19):13482. doi: 10.1021/acs.jmedchem.2c01533. Epub 2022 Oct 3. Erratum for: J Med Chem. 2022 Sep 8;65(17):11485-11496. PMID: 36190771; PMCID: PMC9574857. 4: Gan LM, Lagerström-Fermér M, Ericsson H, Nelander K, Lindstedt EL, Michaëlsson E, Kjaer M, Heijer M, Whatling C, Fuhr R. Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers. Br J Clin Pharmacol. 2019 Apr;85(4):762-770. doi: 10.1111/bcp.13855. Epub 2019 Feb 18. PMID: 30618054; PMCID: PMC6422671. 5: Jurva U, Weidolf L, Sandinge AS, Leandersson C, Ekdahl A, Li XQ, Antonsson T, Sundell J, Westerlund K, Amilon C, Inghardt T, Gopaul VS. Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans. Drug Metab Dispos. 2023 Jan 18:DMD-AR-2022-001099. doi: 10.1124/dmd.122.001099. Epub ahead of print. PMID: 36653117. 6: Bhattacharya C, Sandinge AS, Bragg RA, Heijer M, Yan J, Andersson LC, Jurva U, Pelay-Gimeno M, Vaes WHJ, de Ligt RAF, Gränfors M, Amilon C, Lindstedt EL, Menakuru SR, Garkaviy P, Weidolf L, Gopaul VS. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, Following Administration of an Oral Radiolabeled Microtracer Dose in Humans. Drug Metab Dispos. 2023 Jan 13:DMD- AR-2022-001100. doi: 10.1124/dmd.122.001100. Epub ahead of print. PMID: 36639243. 7: Walles M, Pähler A, Isin EM, Ahlqvist MM. Meeting report of the 3rd European Biotransformation Workshop. Xenobiotica. 2023 Jan 31:1-5. doi: 10.1080/00498254.2023.2173105. Epub ahead of print. PMID: 36692101.